ADVANCED PANCREATIC CANCER WITH KRAS MUTATION

Clinical trials for ADVANCED PANCREATIC CANCER WITH KRAS MUTATION explained in plain language.

Never miss a new study

Get alerted when new ADVANCED PANCREATIC CANCER WITH KRAS MUTATION trials appear

Sign up with your email to follow new studies for ADVANCED PANCREATIC CANCER WITH KRAS MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Hard-to-Treat cancers: BLU-924 targets KRAS mutations

Disease control Recruiting now

This study tests a new drug called BLU-924 in people with advanced pancreatic, lung, or colorectal cancer that has a specific KRAS mutation. The drug aims to block the mutated protein and slow or shrink the cancer. The trial will check safety, side effects, and how well the drug …

Matched conditions: ADVANCED PANCREATIC CANCER WITH KRAS MUTATION

Phase: PHASE1, PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control

Last updated Jun 10, 2026 13:28 UTC

ADVANCED PANCREATIC CANCER WITH KRAS MUTATION

Get alerted when new ADVANCED PANCREATIC CANCER WITH KRAS MUTATION trials appear

New hope for Hard-to-Treat cancers: BLU-924 targets KRAS mutations